2019 Future of Cognitive Impairment Associated With Schizophrenia (CIAS) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

February 2019 | 80 pages | ID: 2CE77164A78EN
VPAResearch

Abstracts

The global demand for Cognitive Impairment Associated With Schizophrenia (CIAS) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline companies from advancing their products into Phase 3 or Phase 4.

Cognitive Impairment Associated With Schizophrenia (CIAS) Report Description-

The 2019 pipeline study on Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline compounds.

The Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline guide presents information on all active drugs currently being developed for Cognitive Impairment Associated With Schizophrenia (CIAS). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Cognitive Impairment Associated With Schizophrenia (CIAS) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Cognitive Impairment Associated With Schizophrenia (CIAS) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline report includes-

• An overview of Cognitive Impairment Associated With Schizophrenia (CIAS) disease including symptoms, causes, diagnosis and available treatment options is provided.
• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise count of Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline
• Company wise list of Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline
• Mechanism of Action wise Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline
• For each pipeline candidate, the following details are provided
• Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials/Results
• Company Overview and Recent Developments

REASONS TO BUY

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into companies participating in Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. GLOBAL COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE OVERVIEW

2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. EXECUTIVE SUMMARY

3.1 Cognitive Impairment Associated With Schizophrenia (CIAS) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
  3.2.1 Pre-clinical
  3.2.2 Discovery
  3.2.3 Phase
  3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
  3.3.1 Phase
  3.3.2 Pre-registration
3.4 Companies involved in Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline, H1- 2019
3.5 Mechanism of Action wise Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Candidates

4 ANVYL LLC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

4.1 Anvyl LLC Business Profile
4.2 Anvyl LLC Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
4.3 Drug Snapshot
  4.3.1 Originator
  4.3.2 Collaborator/Co-Developer
  4.3.3 Route of Administration
  4.3.4 Orphan Drug/Fast Track/Special Designation
  4.3.5 Geography
  4.3.6 Type of Molecular Entity
  4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 ASTELLAS PHARMA INC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

5.1 Astellas Pharma Inc Business Profile
5.2 Astellas Pharma Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
5.3 Drug Snapshot
  5.3.1 Originator
  5.3.2 Collaborator/Co-Developer
  5.3.3 Route of Administration
  5.3.4 Orphan Drug/Fast Track/Special Designation
  5.3.5 Geography
  5.3.6 Type of Molecular Entity
  5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 ASTRAZENECA PLC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

6.1 AstraZeneca Plc Business Profile
6.2 AstraZeneca Plc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
6.3 Drug Snapshot
  6.3.1 Originator
  6.3.2 Collaborator/Co-Developer
  6.3.3 Route of Administration
  6.3.4 Orphan Drug/Fast Track/Special Designation
  6.3.5 Geography
  6.3.6 Type of Molecular Entity
  6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 AUTIFONY THERAPEUTICS LTD COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

7.1 Autifony Therapeutics Ltd Business Profile
7.2 Autifony Therapeutics Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
7.3 Drug Snapshot
  7.3.1 Originator
  7.3.2 Collaborator/Co-Developer
  7.3.3 Route of Administration
  7.3.4 Orphan Drug/Fast Track/Special Designation
  7.3.5 Geography
  7.3.6 Type of Molecular Entity
  7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 BIOGEN INC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

8.1 Biogen Inc Business Profile
8.2 Biogen Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
8.3 Drug Snapshot
  8.3.1 Originator
  8.3.2 Collaborator/Co-Developer
  8.3.3 Route of Administration
  8.3.4 Orphan Drug/Fast Track/Special Designation
  8.3.5 Geography
  8.3.6 Type of Molecular Entity
  8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 BIOMED SL COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

9.1 Biomed SL Business Profile
9.2 Biomed SL Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
9.3 Drug Snapshot
  9.3.1 Originator
  9.3.2 Collaborator/Co-Developer
  9.3.3 Route of Administration
  9.3.4 Orphan Drug/Fast Track/Special Designation
  9.3.5 Geography
  9.3.6 Type of Molecular Entity
  9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 BOEHRINGER INGELHEIM GMBH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

10.1 Boehringer Ingelheim GmbH Business Profile
10.2 Boehringer Ingelheim GmbH Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
10.3 Drug Snapshot
  10.3.1 Originator
  10.3.2 Collaborator/Co-Developer
  10.3.3 Route of Administration
  10.3.4 Orphan Drug/Fast Track/Special Designation
  10.3.5 Geography
  10.3.6 Type of Molecular Entity
  10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 BRISTOL-MYERS SQUIBB CO COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

11.1 Bristol-Myers Squibb Co Business Profile
11.2 Bristol-Myers Squibb Co Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
11.3 Drug Snapshot
  11.3.1 Originator
  11.3.2 Collaborator/Co-Developer
  11.3.3 Route of Administration
  11.3.4 Orphan Drug/Fast Track/Special Designation
  11.3.5 Geography
  11.3.6 Type of Molecular Entity
  11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 CADENT THERAPEUTICS COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

12.1 Cadent Therapeutics Business Profile
12.2 Cadent Therapeutics Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
12.3 Drug Snapshot
  12.3.1 Originator
  12.3.2 Collaborator/Co-Developer
  12.3.3 Route of Administration
  12.3.4 Orphan Drug/Fast Track/Special Designation
  12.3.5 Geography
  12.3.6 Type of Molecular Entity
  12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13 ELI LILLY AND CO COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

13.1 Eli Lilly and Co Business Profile
13.2 Eli Lilly and Co Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
13.3 Drug Snapshot
  13.3.1 Originator
  13.3.2 Collaborator/Co-Developer
  13.3.3 Route of Administration
  13.3.4 Orphan Drug/Fast Track/Special Designation
  13.3.5 Geography
  13.3.6 Type of Molecular Entity
  13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14 F. HOFFMANN-LA ROCHE LTD COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

14.1 F. Hoffmann-La Roche Ltd Business Profile
14.2 F. Hoffmann-La Roche Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
14.3 Drug Snapshot
  14.3.1 Originator
  14.3.2 Collaborator/Co-Developer
  14.3.3 Route of Administration
  14.3.4 Orphan Drug/Fast Track/Special Designation
  14.3.5 Geography
  14.3.6 Type of Molecular Entity
  14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15 HEPTARES THERAPEUTICS LTD COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

15.1 Heptares Therapeutics Ltd Business Profile
15.2 Heptares Therapeutics Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
15.3 Drug Snapshot
  15.3.1 Originator
  15.3.2 Collaborator/Co-Developer
  15.3.3 Route of Administration
  15.3.4 Orphan Drug/Fast Track/Special Designation
  15.3.5 Geography
  15.3.6 Type of Molecular Entity
  15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16 INTRA-CELLULAR THERAPIES INC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

16.1 Intra-Cellular Therapies Inc Business Profile
16.2 Intra-Cellular Therapies Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
16.3 Drug Snapshot
  16.3.1 Originator
  16.3.2 Collaborator/Co-Developer
  16.3.3 Route of Administration
  16.3.4 Orphan Drug/Fast Track/Special Designation
  16.3.5 Geography
  16.3.6 Type of Molecular Entity
  16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments

17 IPROTEOS SL COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

17.1 Iproteos SL Business Profile
17.2 Iproteos SL Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
17.3 Drug Snapshot
  17.3.1 Originator
  17.3.2 Collaborator/Co-Developer
  17.3.3 Route of Administration
  17.3.4 Orphan Drug/Fast Track/Special Designation
  17.3.5 Geography
  17.3.6 Type of Molecular Entity
  17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments

18 PFIZER INC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

18.1 Pfizer Inc Business Profile
18.2 Pfizer Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
18.3 Drug Snapshot
  18.3.1 Originator
  18.3.2 Collaborator/Co-Developer
  18.3.3 Route of Administration
  18.3.4 Orphan Drug/Fast Track/Special Designation
  18.3.5 Geography
  18.3.6 Type of Molecular Entity
  18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments

19 SK BIOPHARMACEUTICALS CO LTD COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

19.1 SK Biopharmaceuticals Co Ltd Business Profile
19.2 SK Biopharmaceuticals Co Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
19.3 Drug Snapshot
  19.3.1 Originator
  19.3.2 Collaborator/Co-Developer
  19.3.3 Route of Administration
  19.3.4 Orphan Drug/Fast Track/Special Designation
  19.3.5 Geography
  19.3.6 Type of Molecular Entity
  19.3.7 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments

20 SPHERIUM BIOMED SL COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

20.1 Spherium Biomed SL Business Profile
20.2 Spherium Biomed SL Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
20.3 Drug Snapshot
  20.3.1 Originator
  20.3.2 Collaborator/Co-Developer
  20.3.3 Route of Administration
  20.3.4 Orphan Drug/Fast Track/Special Designation
  20.3.5 Geography
  20.3.6 Type of Molecular Entity
  20.3.7 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments

21 SUVEN NEUROSCIENCES INC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

21.1 Suven Neurosciences Inc Business Profile
21.2 Suven Neurosciences Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
21.3 Drug Snapshot
  21.3.1 Originator
  21.3.2 Collaborator/Co-Developer
  21.3.3 Route of Administration
  21.3.4 Orphan Drug/Fast Track/Special Designation
  21.3.5 Geography
  21.3.6 Type of Molecular Entity
  21.3.7 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments

22 TAKEDA PHARMACEUTICAL CO LTD COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

22.1 Takeda Pharmaceutical Co Ltd Business Profile
22.2 Takeda Pharmaceutical Co Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
22.3 Drug Snapshot
  22.3.1 Originator
  22.3.2 Collaborator/Co-Developer
  22.3.3 Route of Administration
  22.3.4 Orphan Drug/Fast Track/Special Designation
  22.3.5 Geography
  22.3.6 Type of Molecular Entity
  22.3.7 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments

23 VANDA PHARMACEUTICALS INC COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE DETAILS

23.1 Vanda Pharmaceuticals Inc Business Profile
23.2 Vanda Pharmaceuticals Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
23.3 Drug Snapshot
  23.3.1 Originator
  23.3.2 Collaborator/Co-Developer
  23.3.3 Route of Administration
  23.3.4 Orphan Drug/Fast Track/Special Designation
  23.3.5 Geography
  23.3.6 Type of Molecular Entity
  23.3.7 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments

24. LATEST COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) DRUG PIPELINE DEVELOPMENTS, 2019

25. APPENDIX

25.1 About Us
25.2 Sources and Methodology
25.3 Contact Information